XML 77 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Goodwill and Intangible Assets (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Nov. 07, 2022
Finite-Lived Intangible Assets [Line Items]        
In-process research and development $ 331.1   $ 40.2  
Contingent consideration 372.5   375.0  
Business Combination Contingent Consideration Liability Payments (9.7)      
Intangible asset disposal & impairment charges 32.0 $ 0.0    
Goodwill 10,573.2   10,425.8  
Oyster Point Pharma Acquisition        
Finite-Lived Intangible Assets [Line Items]        
Contingent consideration 60.0      
Goodwill 5.9      
Famy Life Sciences Acquisition        
Finite-Lived Intangible Assets [Line Items]        
Goodwill       $ 89.3
Product Rights And Licenses | Oyster Point Pharma Acquisition        
Finite-Lived Intangible Assets [Line Items]        
Acquired intangible assets 334.0      
In Process Research and Development | Famy Life Sciences Acquisition        
Finite-Lived Intangible Assets [Line Items]        
Acquired intangible assets       $ 290.0
Emerging Markets (2)        
Finite-Lived Intangible Assets [Line Items]        
Goodwill 1,335.4   1,334.7  
JANZ        
Finite-Lived Intangible Assets [Line Items]        
Goodwill 680.4   689.0  
Greater China        
Finite-Lived Intangible Assets [Line Items]        
Goodwill 940.6   940.6  
Other Current Liabilities [Member]        
Finite-Lived Intangible Assets [Line Items]        
Contingent consideration 65.4   $ 64.4  
Business Combination Contingent Consideration Liability Payments (9.7)      
Reconciling items:        
Finite-Lived Intangible Assets [Line Items]        
Intangible asset disposal & impairment charges $ 32.0 $ 0.0